PROS1 and cancer: Our results also indicated that high PROS1 expression was correlated with worse PD1 outcomes in kidney renal clear cell carcinoma (Braun2020_PD1 Clear), melanoma (Liu2019_PD1 Ipi_Naive, Gide2019_PD1, and Riaz2017_PD1 Ipi_Naive), PD-ligand 1 (LI) (BladderMariathasan2018_PDL1 mUC), ACT melanoma (Lauss2017_ACT), and CTLA4 (Nathanson2017_CTLA4 Post) but achieved good CTLA4 therapeutic outcomes in melanoma (Nathanson2017_CTLA4 Pre), and kidney renal clear cell carcinoma (Miao2018_ICB Clear) cancer cohorts (Fig. 14B).